ArticleBMC public health2016
The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy.
Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.BMC medical research methodology · 2018Pooled it
- Aspects that facilitate access to care for viral hepatitis: An evaluative research.Sao Paulo medical journal = Revista paulista de medicina · 2024Article
- Public knowledge and attitudes toward liver diseases and liver cancer in the Brazilian population: a cross sectional study.Lancet regional health. Americas · 2023Article
- The reasons to include the serology of human T-lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) in the clinical follow-up of patients with viral hepatitis B and C in Brazil.PLoS neglected tropical diseases · 2020Article
- The Elimination of Hepatitis C as a Public Health Threat.Cold Spring Harbor perspectives in medicine · 2020Review
- Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil.BMC infectious diseases · 2020Article
- Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.Liver international : official journal of the International Association for the Study of the Liver · 2019Review
- Hepatitis C elimination: a Public Health Perspective.Current treatment options in gastroenterology · 2019Review
- Characteristics of a hepatitis C patient cohort at a specialized tertiary care facility: Identifying criteria to improve the allocation of public health resources.Clinics (Sao Paulo, Brazil) · 2019Article
- Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973-2017).Hepatology, medicine and policy · 2018Review
- Epidemiology of viral hepatitis in the Republic of Congo: review.BMC research notes · 2017Review
- Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.BMC gastroenterology · 2017Review
- Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.BMC infectious diseases · 2017Article
- Age-standardized mortality rates related to viral hepatitis in Brazil.BMC infectious diseases · 2017Article
- Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In response to the global outcry of hepatitis epidemic and the need to improve the nation's public health response, the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be accessed through sustainable and universal means. DISCUSSION: This paper describes the unique process of implementing evidence-informed policy to respond to hepatitis C epidemic through the update of hepatitis C treatment in Brazil based on the estimate of disease prevalence, current international guidelines, and the cost-effectiveness impact in the Brazilian Unified Health System. Through a debate of an experience report, the authors underlie the strategic plan implemented according to the situation analysis that emphasized the need to improve its current response over a relatively short-term period. The comprehensive response is detailed comprising three main objectives: improve treatment outcomes by evaluating and incorporating new and effective medications at a sustainable price; elaborate on clinical guidelines to treat hepatitis C patients; and develop awareness and diagnosis campaigns targeted at the population of interest. In this scenario, Brazil was able to obtain an unprecedented discount for a high-medium income country; provided treatment to more than 7000 individuals in the last 2 months of 2015; and expects to treat 38,000 new patients in 2016. The remarkable process applied in Brazil was developed according to epidemiological data and scientific evidence, and it was motivated by the engagement of the country in the Sustainable Development Goals, which may inspire other developing countries to identify ways to achieve these goals by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.